A $2 billion government investment to bring Moderna to Australia is paying dividends before a vaccine has rolled off its Melbourne production line, according to the US pharmaceutical giant, as scrutiny lingers around the landmark deal.
The company will on Tuesday release a report claiming the new domestic capability will help Australia avoid $4.8 billion in future pandemic costs and has already delivered jobs and research benefits.
It comes as the national audit office finalises its own report on the then-Morrison government’s deal to bring the company to Australia to produce mRNA vaccines at the expense of local rival CSL.
Want to know how this story ends?
Become a subscriber for complete access to all stories on InnovationAus.com and our daily newsletter.
Do you know more? Contact James Riley via Email.